ArticlebioRxiv : the preprint server for biology2025
BCG vaccination elicits protection against Mtb infection mediated by two phases of T cell immunity.
Abiola F Ogunsola, Rocky Lai, Kelly Cavallo, Gillian L Beamer, Samuel M Behar
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
Abiola F OgunsolaMD/PhD Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Rocky LaiDepartment of Microbiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Kelly CavalloDepartment of Microbiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Gillian L BeamerTexas Biomedical Research Institute, San Antonio, Texas, USA.
Samuel M BeharMD/PhD Program, Morningside Graduate School of Biomedical Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0002-3374-6699 Funding
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93019C00071 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI FORTUNE, SARAH · 2019 to 2025
$57.3MSystems Genetics of TuberculosisP01AI181898 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SAMUEL M BEHAR · 2024 to 2026
$10.5MTRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5MTuberculosis and T cell RecognitionR01AI123286 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BEHAR, SAMUEL M, FORTUNE, SARAH · 2016 to 2020
$3.5MPredicting tuberculosis outcomes using genotypic and biomarker signaturesR01HL145411 · NHLBI · TUFTS UNIVERSITY BOSTON · PI BEAMER, GILLIAN L · 2019 to 2023
$3.4MHypoxia, tuberculosis, and T cell dysfunctionR01AI172905 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SAMUEL M BEHAR · 2023 to 2026
$3.0MMedical Scientist Training at UMCMST32GM159591 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Read Pukkila-Worley · 2025 to 2026
$2.0MNHLBI NIH HHS R01 HL145411NIAID NIH HHS 75N93019C00071NIAID NIH HHS P01 AI181898NIAID NIH HHS R01 AI123286NIAID NIH HHS R01 AI172905NIAID NIH HHS T32 AI007349NIGMS NIH HHS T32 GM159591
6 · The paper itselfAbstract
Vaccine development for tuberculosis is a global priority. Our studies using Collaborative Cross (CC) mice show that genetic diversity influences the efficacy of BCG, the most widely used TB vaccine. BCG vaccination of CC042 mice reduces their lung bacillary burden and increases their survival following low-dose aerosol
Identifiers
PMID41279457
PMCPMC12636623
What OpenQuestion holds
Textmetadata
Read underepoch 390